Epidermal growth factor receptor (EGFR) mutations are commonly found in non‐small cell lung cancer (NSCLC), with a prevalence of 10%–20% in Caucasian patients and 30%–40% in Asian patients with advanced NSCLC.1, 2. Here, EGFR is linked to non-small cell lung carcinoma.